mProX™ Human SLC47A1 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-0922-KX1561	Magic™ Human SLC47A1 in Vitro Drug screening assay	Human	Caco-2, MDCK, HEK293, CHO, membrane vesicles, and various transfected cells lines	Activity Assay (High throughput screening assays; Large scale single dose, duplicate profiling; IC50 profiling; Ki determination assay; Substrate determination assay )

Product Information

Target Protein

SLC47A1

Target Family

SLC Transporter

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Transporter Cell Lines

Target Research Area

CNS Research

Related Diseases

Smith-Magenis Syndrome; Alzheimer Disease

Gene ID

55244

UniProt ID

Q96FL8

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SLC47A1 belongs to the MATE family of transporters, which eliminate harmful electrolytes from the body through the excretion of urine and bile. Both kidney and liver cells express SLC47A1 on the apical side of their membranes. The transporter SLC47A1/MATE1 is in charge of excreting metformin into the bile. An earlier but still widely used drug for type II diabetes is metformin, especially for people who are obese or overweight. In order to assist control type II diabetes, metformin lowers blood glucose, triglycerides, and low-density lipoproteins while also raising peripheral insulin sensitivity. Metformin increases hepatic insulin sensitivity, inhibits gluconeogenesis, and activates AMPK in the liver. Metformin is pumped into the bile by the SLC47A1/MATE1 transporter, where it is excreted by the kidneys and urine. The customized SLC47A1 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Kimberly

The protocol of SLC47A1 cell line was straightforward, and the results were consistent. Sep 14 2022

chat Verified Customer

chat Charles

The convenience of the SLC47A1 cell line has significantly streamlined my workflow. May 21 2020

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 SLC47A1 is upregulated during ferroptosis.

The upregulation of SLC47A1 and ANO3 protein expression after RSL3 therapy was further verified by Western blot analysis, which was dose- and time-dependent. RSL3 downregulated the protein expression of GPX4 as a control.

Ref: Lin, Zhi, et al. "The lipid flippase SLC47A1 blocks metabolic vulnerability to ferroptosis." Nature Communications 13.1 (2022): 7965.

Pubmed: 36575162

DOI: 10.1038/s41467-022-35707-2

Research Highlights

Mice treated with a ferroptosis inducer that had its anticancer activity boosted by pharmacological or genetic inhibition of the PPARA-SLC47A1 pathway. These results demonstrate a direct molecular connection between lipid transporters and ferroptosis, which could offer metabolic targets for circumventing medication resistance.
Lin, Zhi, et al. "The lipid flippase SLC47A1 blocks metabolic vulnerability to ferroptosis." Nature Communications 13.1 (2022): 7965.
Pubmed: 36575162 DOI: 10.1038/s41467-022-35707-2

AGEs reduce the expression of MATE1/SLC47A1, raising the possibility of proximal tubular damage.
Mizuno, Tomohiro, et al. "Significance of downregulation of renal organic cation transporter (SLC47A1) in cisplatin-induced proximal tubular injury." OncoTargets and therapy (2015): 1701-1706.
Pubmed: 26203260 DOI: 10.2147/OTT.S86743